Enduring CME activity from the School of Breast Oncology: 2018 Mid-Year Video Update

Enduring CME activity from the School of Breast Oncology: 2018 Mid-Year Video Update is organized by Physicians' Education Resource LLC (PER).

Release Date: September 28 2018
Expiration Date: September 28 2019

Target Audience:
This educational activity is directed toward medical, surgical, and radiation oncologists involved in the treatment and management of patients with breast cancer. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other healthcare professionals interested in the treatment of breast cancer may also participate.

Accreditation:
Physicians' Education Resource®, LLC designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Physicians' Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669, for 2.0 Contact Hours.

Description:
Since 2003, the School of Breast Oncology® (SOBO®) has revolutionized the advancement of patient care by offering world-class comprehensive continuing education programming for oncologists and healthcare professionals involved in the treatment of breast cancer. To extend this educational initiative further, the SOBO®: 2018 Mid-Year Video Update aired on August 27, 2018, as a live-stream, interactive broadcast featuring leading experts in the field of breast cancer who provided a comprehensive overview of noteworthy data presented at recent international society meetings. The expert panel also discussed and debated the clinical application of these data and the future direction of the treatment landscape in breast cancer.

This enduring CME activity is an archive of the live broadcast that has been edited into modules for ease of access. This activity will help you to keep pace with rapidly emerging data and advancing treatment paradigms in breast cancer by augmenting your knowledge and clinical competence in several areas, including:

Integrating prognostic genomic assays to individualize treatment selection for early-stage, hormone receptor?positive (HR+)/HER2-negative breast cancers
Evolving paradigms in (neo)adjuvant therapy for HR+, HER2+, and triple-negative breast cancers
Clinical insights regarding endocrine, cytotoxic, targeted, and immunotherapeutic agents for the treatment of metastatic breast cancer, including current treatment options and emerging agents
Trends, challenges, and controversies in the locoregional management of early-stage and locally advanced breast cancers
SOBO®: 2018 Mid-Year Video Update brings conference-caliber education to the convenience of your screen!

Benefits of Attending
• Insights into using predictive and prognostic biomarkers for treatment selection
• Tactics for individualizing therapy for early-stage and locally advanced breast cancers
• Strategies for integrating new agents for metastatic disease
• Innovations in locoregional management approaches

Learning Objectives:
Upon completion of this activity, you should be better prepared to:
• Assess recently presented efficacy and safety data from clinical trials conducted in the setting of breast cancer
• Explain key recent findings concerning tumor testing to help optimize care for patients with breast cancer
• Appraise recent evidence regarding treatment sequencing and combination strategies for patients who may be candidates for new therapies for breast cancer
• Develop evidence-based treatment plans for patients with breast cancer, incorporating new treatment options when appropriate